翰宇藥業(300199.SZ)擬聯合翰宇大理及致遠生物共設翰宇原創
格隆匯 9 月 22日丨翰宇藥業(300199.SZ)公佈,為進一步提高公司的競爭力,打造公司產業鏈全營銷渠道,拓展公司的業務廣度,公司擬聯合翰宇生物科技(大理)有限公司(“翰宇大理”)、深圳華祥致遠生物科技中心(有限合夥)(“致遠生物”)共同出資設立深圳翰宇原創生物科技有限公司(“翰宇原創”)。
公司註冊資本擬為人民幣600萬元。股東各方均以貨幣現金方式出資。其中:翰宇藥業出資人民幣360萬元,佔註冊資本總額的60%;翰宇大理出資人民幣150萬元,佔註冊資本總額的25%;致遠生物出資人民幣90萬元,佔註冊資本總額的15%。
鑑於翰宇原創尚未註冊成立,翰宇藥業已申請“Hybio Original翰宇原創”系列商標,待公司獲得“Hybio Original翰宇原創”系列商標註冊證後,將“HybioOriginal翰宇原創”系列商標轉讓給翰宇原創,具體轉讓時間與轉讓價格以最終簽訂協議為準。
此次投資旨在藉助公司自身多肽研究和品質優勢,聯合各方優質資源,打造和完善公司產業鏈全營銷渠道,實現與公司現有面向企業的營銷網絡形成戰略渠道互補。同時,通過設立翰宇原創拓展公司的業務廣度,以推動公司產業多渠道協同發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.